Treatment of autoimmune blistering diseases (AIBDs) has historically relied on systemic corticosteroids, but intravenous immunoglobulin (IVIG) has been shown in randomized clinical trials to be safe and highly effective in the treatment of pemphigus vulgaris and bullous pemphigoid.
growing body of high-quality evidence supporting IVIG's efficacy and safety in the treatment of AIBDs, we sought to similarly evaluate coverage policies among selected private and public payers in the United States.
Methods | To determine coverage policies for IVIG, we used a modification of the protocol described by Wang et al. 4, 5 We identified coverage policies using the websites of each state's Medicaid program and the Centers for Medicare and Medicaid Services. We identified the top 10 private health insurance providers by market share using the National Association of Insurance Commissioners 2015 market share report. Results | All 9 of the private payers assessed listed AIBD as a covered disease. Data from private insurance companies are shown in the Microbiological studies are often performed concurrently with histologic study of skin biopsy specimens to evaluate suspected infection. These studies may require an additional biopsy, with possible patient discomfort, procedure-related risk, and increased laboratory time and cost. 1,2 Despite the commonality of this practice, data on the utility of tissue microbiological studies are limited. In this study, we evaluate the yield of skin microbiology studies and how often they influence care in the general dermatology population.
Methods | We searched the Partners Healthcare registry for patients for whom both pathology and microbiology studies were ordered on skin biopsy specimens by dermatologists at Brigham & Women's Hospital and Massachusetts General Hospital from 2000 to 2015. Medical record review was conducted on a random sample of 150 patients with complete clinical documentation who met inclusion criteria. Each set of microbiology results was defined as truepositive, false-positive, true-negative, or false-negative based on the documented final clinical interpretation. We defined false-negative as cases where clinical suspicion overruled negative data and false-positive as cases where findings showed clinically nonrelevant organisms such as skin commensals. Microbiology sets were categorized based on positive result interpretation (eg, a hypothetical set with true-negative bacterial culture, false-positive Gram stain, true-positive acidfast bacillus culture, and true-negative fungal stain and culture would be categorized as true-positive). The study was approved by the Partners institutional review board. Written informed consent was not required because this was a retrospective study.
Results | Of 150 patients, 138 (92%) were seen in outpatient dermatology clinics and 65 (43.3%) did not have a documented history of immunosuppression ( Table 1) . Infection was listed among the top differential diagnoses in 105 (70%) of patients ( Table 2 ). The most common microbiological studies were bacterial culture (144 patients, 96%), Gram stain (123 patients, 82%), and fungal culture (123 patients, 82%).
Gram stains were positive in 15 microbiology sets (12.2%), fungal stains were positive in 0 (0%), and acid-fast bacilli stains were positive in 2 (1.8%) cases. Bacterial cultures were positive in 72 (50%), fungal cultures were positive in 6 (4.9%), and acid-fast bacillus cultures were positive in 5 (4.6%). Microbiological studies were 70.7% (106 of 150) concordant with dermatopathology results: both suggested infection in 21 (14.0%) cases; both showed no evidence of infection in 85 (56.7%). The 150 sets of microbiology studies had a sensitivity of 80.8% (95%
